Loading...
XNASTLSA
Market cap74mUSD
Dec 27, Last price  
0.67USD
1D
-3.80%
1Q
-33.37%
IPO
-59.70%
Name

Tiziana Life Sciences Ltd

Chart & Performance

D1W1MN
XNAS:TLSA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-17.52%
Rev. gr., 5y
%
Revenues
0k
189,887199,600793,479126,921134,72590,5510003,0000000000000
Net income
-18m
L+9.15%
00000000000000000-23,417,000-16,208,000-17,691,000
CFO
-16m
L-19.97%
00000000000000000-21,762,000-19,615,000-15,698,000

Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
URL
https://www.tizianalifesciences.com
IPO date
Jul 14, 2008
Employees
9
Domiciled in
GB
Incorporated in
BM

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
8,113
14,637
14,204
Unusual Expense (Income)
NOPBT
(8,113)
(14,637)
(14,204)
NOPBT Margin
Operating Taxes
449
811
(3,240)
Tax Rate
NOPAT
(8,562)
(15,448)
(10,964)
Net income
(17,691)
9.15%
(16,208)
-30.79%
(23,417)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
24
129
BB yield
-0.14%
Debt
Debt current
138
122
1,355
Long-term debt
356
608
Deferred revenue
Other long-term liabilities
Net debt
(5,243)
(19,198)
(40,831)
Cash flow
Cash from operating activities
(15,698)
(19,615)
(21,762)
CAPEX
(22)
Cash from investing activities
(1,253)
(3,996)
130
Cash from financing activities
40
(55)
(23)
FCF
(8,466)
(15,518)
(10,925)
Balance
Cash
1,183
18,122
42,186
Long term investments
4,554
1,806
Excess cash
5,737
19,928
42,186
Stockholders' equity
(16,512)
(592)
11,190
Invested Capital
22,295
20,528
31,445
ROIC
ROCE
EV
Common stock shares outstanding
101,526
97,932
Price
0.56
-6.43%
0.60
-37.66%
0.96
-52.48%
Market cap
60,764
-35.37%
94,015
-72.47%
EV
41,566
53,184
EBITDA
(8,017)
(14,586)
(14,063)
EV/EBITDA
Interest
10
7
176
Interest/NOPBT